232 related articles for article (PubMed ID: 30244644)
1. BMS - Consensus statement.
Pitkin J;
Post Reprod Health; 2018 Sep; 24(3):133-138. PubMed ID: 30244644
[TBL] [Abstract][Full Text] [Related]
2. [Current aspects of the treatment of urogenital atrophy (based on the consensus of britain society of menopause)].
Balan VE; Tikhomirova EV; Tsarkova AV; Gadgieva ZK
Urologiia; 2019 Dec; (5):150-154. PubMed ID: 31808652
[TBL] [Abstract][Full Text] [Related]
3. Update on management of genitourinary syndrome of menopause: A practical guide.
Palacios S; Castelo-Branco C; Currie H; Mijatovic V; Nappi RE; Simon J; Rees M
Maturitas; 2015 Nov; 82(3):308-13. PubMed ID: 26261035
[TBL] [Abstract][Full Text] [Related]
4. Treatment of the genitourinary syndrome of menopause.
Palacios S; Mejía A; Neyro JL
Climacteric; 2015; 18 Suppl 1():23-9. PubMed ID: 26366797
[TBL] [Abstract][Full Text] [Related]
5. Genitourinary Syndrome of Menopause.
Shifren JL
Clin Obstet Gynecol; 2018 Sep; 61(3):508-516. PubMed ID: 29787390
[TBL] [Abstract][Full Text] [Related]
6. Treatment of dyspareunia secondary to vulvovaginal atrophy.
Fantasia HC
Nurs Womens Health; 2014; 18(3):237-41. PubMed ID: 24939201
[TBL] [Abstract][Full Text] [Related]
7. Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations.
Lev-Sagie A
Clin Obstet Gynecol; 2015 Sep; 58(3):476-91. PubMed ID: 26125962
[TBL] [Abstract][Full Text] [Related]
8. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
9. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
Reid RL; Black D; Derzko C; Portman D
J Obstet Gynaecol Can; 2020 Mar; 42(3):301-303. PubMed ID: 31932249
[TBL] [Abstract][Full Text] [Related]
10. Ospemifene in the treatment of vulvovaginal atrophy.
Barnes KN; Pearce EF; Yancey AM; Forinash AB
Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
[TBL] [Abstract][Full Text] [Related]
11. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
12. What's new in the world of postmenopausal sex?
Iglesia CB
Curr Opin Obstet Gynecol; 2016 Oct; 28(5):449-54. PubMed ID: 27517339
[TBL] [Abstract][Full Text] [Related]
13. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?
Edwards D; Panay N
Climacteric; 2016 Apr; 19(2):151-61. PubMed ID: 26707589
[TBL] [Abstract][Full Text] [Related]
14. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
Tan O; Bradshaw K; Carr BR
Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
Wurz GT; Kao CJ; DeGregorio MW
Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
[TBL] [Abstract][Full Text] [Related]
16. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
DeGregorio MW; Zerbe RL; Wurz GT
Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
[TBL] [Abstract][Full Text] [Related]
17. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
18. Managing vulvovaginal atrophy after breast cancer.
Sassarini J; Perera M; Spowart K; McAllister K; Fraser J; Glasspool R; Harrand R; Chitoni M; Stallard S; Lumsden MA
Post Reprod Health; 2018 Dec; 24(4):163-165. PubMed ID: 30348046
[TBL] [Abstract][Full Text] [Related]
19. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety.
Potter N; Panay N
Climacteric; 2021 Feb; 24(1):19-24. PubMed ID: 32990054
[TBL] [Abstract][Full Text] [Related]
20. Assessment of ospemifene or lubricants on clinical signs of VVA.
Constantine G; Graham S; Koltun WD; Kingsberg SA
J Sex Med; 2014 Apr; 11(4):1033-1041. PubMed ID: 24443923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]